Timothy C. Chambers

High Impact

Researcher

UAMS primary University of Arkansas

Also affiliated: Rush University Medical Center (1994); Merck & Co., Inc., Rahway, NJ, USA (United States) (1990); Emory University (1990–1994); Gdańsk University of Technology (2012); United States Military Academy (1988–1990); University of Arkansas Medical Center (2022); Texas Health Dallas (1994); National Jewish Health (1986–1992); Winthrop Rockefeller Foundation (2021); Gdańsk Medical University (2012); University of Colorado Denver (1986–1992)

Faculty Researcher

35 h-index 168 pubs 4,714 cited

Research Areas

Biomedical Subjects

Links

ORCID Research Group

OverviewAI-generated summary

Timothy C. Chambers' research focuses on understanding and developing therapeutic strategies for various cancers, with a particular emphasis on cancer stem-like cells and drug resistance mechanisms. His work has investigated the anti-cancer activity of compounds such as monensin and salinomycin analogs, exploring their efficacy in both 2D and 3D models of breast and glioblastoma. Chambers has also studied the synthesis and anticancer potential of novel colchicine derivatives.

Further investigations include examining the susceptibility of primary acute lymphoblastic leukemia cells to microtubule depolymerization and exploring distinct cell death pathways. His research group collaborates with other faculty members at the University of Arkansas for Medical Sciences, including Joshua M. Eichhorn, Alicja Urbaniak, Megan R. Reed, and Billie Heflin, on projects related to these areas. Chambers' scholarship is recognized by a high h-index of 35 and over 4,600 citations across 168 publications, indicating significant impact in his field.

Metrics

h-index: 35
Publications: 168
Citations: 4,714

Selected Publications

Evaluation of the Activity of Monensin and Its Analogs for Modulation of Stem-like Cell Functionality in 2D and 3D Breast Cancer Models (2025)

ACS Pharmacology & Translational Science 1 citation DOI OpenAlex
Multicellular tumor-stromal interactions recapitulate aspects of therapeutic response and human oncogenic signaling in a 3D disease model for H3K27M-altered DIPG (2025)

Oncogene 7 citations DOI OpenAlex
Monensin and Its Analogs Exhibit Activity Against Breast Cancer Stem-Like Cells in an Organoid Model (2025)

bioRxiv (Cold Spring Harbor Laboratory) DOI OpenAlex
Data from Key role for Bak activation and Bak-Bax interaction in the apoptotic response to vinblastine (2023)

DOI OpenAlex
Anti-glioblastoma activity of monensin and its analogs in an organoid model of cancer (2022)

Biomedicine & Pharmacotherapy 25 citations DOI OpenAlex
Monensin and its analogues show anti‐glioblastoma activity in an organoid model of cancer (2022)

The FASEB Journal DOI OpenAlex
Primary acute lymphoblastic leukemia cells are susceptible to microtubule depolymerization in G1 and M phases through distinct cell death pathways (2022)

Journal of Biological Chemistry 3 citations DOI OpenAlex
Phosphoproteomics Provides Novel Insights into the Response of Primary Acute Lymphoblastic Leukemia Cells to Microtubule Depolymerization in G1 Phase of the Cell Cycle (2021)

ACS Omega 1 citation DOI OpenAlex
Single and double modified salinomycin analogs target stem-like cells in 2D and 3D breast cancer models (2021)

Biomedicine & Pharmacotherapy 13 citations DOI OpenAlex
Abstract PS18-46: Inhibition of breast cancer stem cells in 2- and 3-dimensional culture by novel salinomycin analogs (2021)

Cancer Research DOI OpenAlex